TRYNGOLZA™ (olezarsen) Approved in U.S. for Adults...
Category : Approval/Launch 20 December 2024TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis ev...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
Sanofi, Teva's RELIEVE UCCD Phase 2b Study Meets P...
Category : Clinical Trial Update 20 December 2024Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced th...
Bayer's Phase III QUASAR Study: Positive Results f...
Category : Clinical Trial Update 20 December 2024Bayer announced positive topline results from the global phase III QUASAR study evaluating the effic...
FDA Fast-Tracks Lipocine’s LPCN 1148 for Sarcopeni...
Category : ODD/BTA/FTA Status 20 December 2024Lipocine Inc., a biopharmaceutical company leveraging its proprietary technology platform to augment...
Larimar Reports Positive OLE Data, Advances Nomlab...
Category : Clinical Trial Update 19 December 2024Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments...
Latest Newsletter Post
-
TRYNGOLZA™ (olezarsen) Approved in..
20 December 2024
-
Sanofi, Teva's RELIEVE UCCD Phase 2..
20 December 2024
-
Bayer's Phase III QUASAR Study: Pos..
20 December 2024
-
FDA Fast-Tracks Lipocine’s LPCN 114..
20 December 2024
-
MannKind Reports Phase 3 INHALE-1 R..
19 December 2024
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com